2024 Annual Results Forecast

SZSIJan 18 00:00 · Announcements

ZhiXiang JinTai (688443.SH): Expected loss of 0.731 billion to 0.858 billion yuan in 2024.

On January 17, Glonghui reported that Zhixiang Jintai (688443.SH) published its 2024 annual performance forecast, expecting the net income attributable to shareholders of the parent company to be between -731.28 million yuan and -858.4591 million yuan. Compared to the same period last year, the losses are expected to decrease by 70.0393 million yuan to an increase of 57.1398 million yuan, a year-on-year decrease of 8.74% to an increase of 7.13%. It is expected that the net income attributable to shareholders of the parent company, after deducting non-recurring gains and losses, will be between -738.336 million yuan and -865.5151 million yuan, compared to the same period last year.

Gelonghui FinanceJan 17 21:21

Zhixiang Jintai (688443.SH): The new drug application for Sileweimi monoclonal antibody injection has been accepted.

Gelonghui, January 14 - Zhixiang Jintai (688443.SH) announced that the company's Sileweimi monoclonal antibody injection (GR1801 injection) has reached the primary efficacy endpoint in a phase III clinical trial for passive immunity indications after suspected exposure to rabies virus in adults. The company has submitted a new drug marketing application to the National Medical Products Administration (NMPA) Drug Evaluation Center (CDE), and it has been accepted. Sileweimi monoclonal antibody injection is a recombinant fully human-derived dual-specific antibody against rabies virus (Rabies Virus, RABV) independently developed by the company, registered as a therapeutic Pharmaceutical.

Gelonghui FinanceJan 14 16:17

Kaiyuan Securities: Each subtype of hematological tumors has the potential to hatch "heavyweight bomb" drugs. Pay attention to Innovative Drugs companies.

The subtype of blood tumors is less aggressive with a longer treatment cycle, generally requiring long-term medication. Patients have relatively high viscosity and the potential for the emergence of "blockbuster" drugs.

Zhitong FinanceDec 26, 2024 10:48

Zhixiang Jintai (688443.SH): Liu Zhigang elected as Director.

Gelonghui reported on December 24 that Zhixiang Jintai (688443.SH) announced that on December 24, 2024, the company will hold the first meeting of the second Board of Directors, which reviewed and approved the "Proposal on Election of the Chairman of the Second Board of Directors of the Company". All directors unanimously agreed to elect Mr. Liu Zhigang as the Chairman of the Company's second Board of Directors for a term of three years, the same as thisBoard's term.

Gelonghui FinanceDec 24, 2024 21:00

Zhixiang Jintai (688443): The release of Sileqi monoclonal antibody is expected, and the innovative pipeline is entering a harvest period.

Core view: Leading domestic autoimmune enterprises, innovation pipeline driving medium and long-term development. Zhixiang Jintai was founded in 2015 and is an innovation-driven biopharmaceutical company. The company focuses on three major therapeutic areas: autoimmune diseases, infectious diseases, and tumors.

gf secDec 3, 2024 00:00